Brain Neoplasm
41
4
6
18
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.8%
4 terminated out of 41 trials
81.8%
-4.8% vs benchmark
5%
2 trials in Phase 3/4
22%
4 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 18 completed trials
Clinical Trials (41)
Tumor Related Epilepsy
A Phase 1 Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.
Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements
Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy
Bedside Cranial Ultrasound for Risk-Stratified Imaging in Pediatric Acute Brain Injury
Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Brain Tumors
Surgical Resection of Latent Brain Tumors Prior to Recurrence
EEG-Guided Cognitive Function Preservation in Patients With Brain Tumors
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Non-invasive Intracranial Pressure Monitoring in Brain Tumor Patients
Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography
Cryoablation of Brain Neoplasm
Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects